Risk Prediction of a Multiple Sclerosis Diagnosis by Ho, Joyce C. et al.
1Risk Prediction of a Multiple Sclerosis Diagnosis
Joyce C. Ho∗, Joydeep Ghosh†, KP Unnikrishnan‡
∗ University of Texas at Austin, Austin, TX 78712
Email: joyceho@utexas.edu
†University of Texas at Austin, Austin, TX 78712
Email: ghosh@ece.utexas.edu
‡ NorthShore University HealthSystem, Evanston, IL 60201
Email: KUnnikrishnan@northshore.org
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. The progression and severity
of MS varies by individual, but it is generally a disabling disease. Although medications have been developed to slow the disease
progression and help manage symptoms, MS research has yet to result in a cure. Early diagnosis and treatment of the disease have
been shown to be effective at slowing the development of disabilities. However, early MS diagnosis is difficult because symptoms
are intermittent and shared with other diseases. Thus most previous works have focused on uncovering the risk factors associated
with MS and predicting the progression of disease after a diagnosis rather than disease prediction. This paper investigates the use
of data available in electronic medical records (EMRs) to create a risk prediction model; thereby helping clinicians perform the
difficult task of diagnosing an MS patient. Our results demonstrate that even given a limited time window of patient data, one
can achieve reasonable classification with an area under the receiver operating characteristic curve of 0.724. By restricting our
features to common EMR components, the developed models also generalize to other healthcare systems.
I. INTRODUCTION
Multiple sclerosis (MS) is a chronic, progressive, and incurable autoimmune disease. Inflammation damages the myelin
sheath, the protective coating of nerve cells, and causes signal disruption in the brain and spinal cord. The deterioration of
nerve cells eventually becomes irreversible and leads to the development of disabilities. At least 1.3 million people worldwide
are afflicted with MS with an average onset age of 29 years [1]. The incidence and prevalence rates vary amongst countries
but remains a global problem [1]. Currently no cure exists for MS, but medications can help manage the symptoms, modify
the disease course, and enhance the lifestyle of MS patients. Clinical trials have provided evidence that early diagnosis and
treatment can slow the progression of MS, delaying the development of disabilities [2], [3]. Thus accurate identification of
patients with high risk of developing MS is crucial to limiting the disease activity and prolonging a ‘normal’ patient lifestyle.
Early MS diagnosis is a difficult problem as it lacks a single diagnostic test and common clinical features are shared with
other diseases. Neurologists rely primarily on either the Poser or McDonald diagnostic criteria to classify the disease. The
Poser criteria separates MS into four groups based on attacks, clinical evidence, and paraclinical evidence [4]. The McDonald
diagnostic criteria, developed in 2001, leverages advancements in magnetic resonance imagining (MRI) techniques to facilitate
diagnosis in typical clinical presentations [5]. Recent modifications to McDonald criteria improve the classification applicability
to pediatric, Asian, and Latin American communities [6]. Nonetheless, a neurologist still relies on performing an exclusion
diagnosis in conjunction with the patient’s symptoms and medical history.
The advent of electronic medical records (EMRs) has increased the availability of medical data. Consequently, data mining
and machine learning techniques have been used to develop clinical decision support systems to aid medical professionals. The
problem of identifying patients with high risk of MS is a prime candidate for using EMRs to develop a data-driven prediction
model. This paper investigates the feasibility and performance of a predictive disease model based on existing EMRs. Although
our work is limited to patient data over a 7-year period, we establish a sparse baseline risk prediction model and demonstrate
reasonable classification accuracy.
II. BACKGROUND AND RELATED WORK
The exact nature and cause of MS is still unknown. Epidemiology studies have focused on discovering the variables that
influence the development of MS. Prior research has identified genetic, environmental, and comorbidity risk factors that affect
the disease incidence rates. These variables have been used to build models to predict the diagnosis and progression of the
disease.
A. Risk factors
Genetic susceptibility to MS has been supported by the following risk factors: race, gender, and family history. Genetic
epidemiology studies have demonstrated a rise in disease risk when a family member is affected with MS [7], [8], [9], [10].
The increase in risk is correlated with the degree of kinship [7], [8], [9], [10]. Furthermore, the familial implications may also
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2pertain to other autoimmune diseases [9], [11], [10]. An individual’s race, which is genetically determined, also factors into
the development of the disease. Certain races, such as Asian, Native American, and African American, are less susceptible [7],
[10]. Additionally, MS predominantly afflicts females and exhibit an early onset of the disease than their male counterparts [12],
[10].
The place of residence during a patient’s formative years is one of the environmental factors in the development of MS.
Studies have shown that immigrants migrating before adolescence acquire the risk associated with their new residence while
immigrants moving after adolescence retain their risk of their original residence [13], [14], [10]. The effect of latitude and
hygiene hypothesis may account for the geographic variations beyond genetic factors.
The latitude gradient, a rise in incidence and prevalance rates with an increase in latitude, was previously a prominent
MS feature but has declined in recent years. Sunlight duration, sunlight intensity, and vitamin D levels have been proposed
as potential explanations for this phenomenon [13], [15], [16], [11], [10]. The seasonal vulnerability also demonstrates the
importance of sun exposure as a patient is most vulnerable during the winter [13]. However, there are notable exceptions to
the latitude theory in costal regions of Norway and Japan where a high consumption of fish dampens the lack of sunlight
exposure [13], [10].
The hygiene hypothesis postulated that early exposure to various infectious agents protects the patient against risk of MS [16],
[11], [10]. One infection in particular, Epstein Barr Virus (EBV), has been heavily associated with MS. Individuals with high
anti-EBV antibodies have an increased risk of MS [17]. Additionally, contracting EBV at a later age also increases the likelihood
of developing MS [16], [11], [10]. Other strains of viruses and infections, such as human herpesvirus 6 (HHV6) and Chlamydia
pneumoniae, have been proposed but lack sufficient evidence to support a casual effect on disease risk [15], [11].
One consequence of the hygiene hypothesis is the relationship between vaccinations and the susceptibility to MS. Countries
with higher hygiene standards generally mandate vaccine immunizations to reduce the number of infections. However, during
the late 1990s, concerns grew over the hepatitis B vaccine increasing the risk for MS [18]. Although subsequent studies [19],
[20] failed to find a significant correlation between the vaccine and the development of MS, the hypothesis that vaccinations
may influence the development of the disease should not be dismissed [16].
An individual’s lifestyle, through diet and smoking habits, also factors into the disease risk. Individuals who consume
non-marine meat have higher risk of developing the disease [11]. However, fish and seafood consumption protects against
MS [13], [16], [11], [10]. Marine life has a higher concentration of polyunsaturated fatty acids and antioxidants, which has
anti-inflammatory properties that help suppress the disease process [13], [16]. High consumption of saturated fatty acids during
one’s childhood may cause adolescent obesity, which is associated with an increased risk of MS [10]. Additionally, cigarette
smoking has been shown to influence the development of MS [16], [11], [10].
Shifts in an individual’s hormone levels have also been suggested as factors in the disease process. A decrease in the number
of MS relapses during pregnancy suggests the transient benefits of higher levels of estrogen [16], [12]. A study on British
women showed that the recent use of oral contraceptives reduced the risk of MS [21]. However, a subsequent US study [22]
was unable to obtain evidence that supported the benefits of oral contraceptives.
Other autoimmune disorders and specific cancers have been proposed as potential comorbidities to MS. In a paper that
summarized the environmental features researched in etiological research on MS [11], Lauer noted that inflammatory bowel
disease (IBD), ulcerative colitis, and Type 1 diabetes have the strongest correlations to MS amongst the various autoimmune
disorders. The paper also referenced potential associations with Hodgkin’s, oral, and colon cancers with the caveat that there
was insufficient evidence to support these connections.
B. Predictive models
Predictive studies have primarily focused on the progression of the disease. Bergamaschi et. al [23] identified clinical features
that could help predict the onset of secondary progression, defined by an increase in the Kurtzke’s Expanded Disability Status
Scale (EDSS), using patient data collected in the first year of the disease. The factors discovered in the study were then used
to propose a Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score to predict the risk of reaching the secondary
progression [24]. A recent study suggested the use of EDSS ranking to identify patients at risk for high progression rates 5
years from the onset of the disease [25].
Scoring systems have also been developed to assess the risk of disability. A study showed that MS Functional Composite,
originally proposed as a clinical outcome measure, could be used to determine risk of severe physical disability [26]. The Mag-
netic Resonance Disease Severity Scale (MRDSS) combined MRI measures into a composite score to predict the progression
of physical disabilities [27]. Bazelier [28] derived a score using Cox proportional hazard models to estimate the long-term risk
of osteoporotic and hip fractures in MS patients. Another study conducted by Margaritella et. al [29] used Evoked Potentials
score to predict the progression of disability and identify patients with benign MS.
Limited research has been done with regards to predicting the risk of developing MS. One work predicted MS in patients
with mono symptomatic optic neuritis using MRI examination findings, oligoclonal bands in cerebrospinal fluid (CSF),
immunoglobulin (Ig) G index, and the seasonal time of onset [30]. Thrower [31] suggested the use of clinical characteristics of
optic neuritis and traverse myelitis to identify high-risk MS patients. More recently, De Jager et. al [32] proposed a weighted
3TABLE I: The list of MS features and their associated categories. The order of feature introduction is denoted by the number
next to the category name.
Demographics (1)
Gender
Ethnicity
Race
Age
Family History (1)
MS
Mental Illness
Colon Cancer
Breast Cancer
Lupus
Thyroiditis
Diabetes
Inflammatory Bowel
Autoimmune (2)
Inflammatory Bowel
Celiac
Uveitis
Thyroiditis
Lupus
Rheumatoid arthritis
Sjoren’s syndrome
Bell’s palsy
Guillain Barre
Diabetes
Vitamin D deficiency
Microbial (3)
Measles, mumps, rubella
Epstein Barr Virus
Mental Illness (4)
Bipolar
Schizophrenia
Cancer (5)
Lymphoma
Oral
Breast
Colon
Vaccine (6)
Hepatitis (A+B)
Diphteria, tetanus, pertussis
Polio
Influenza
Measles, mumps, and rubella
Varicella (chicken pox)
Meningococcal
Pneumococcal
Haemophilus influenzae type b
Human Papillomavirus
Reproductive (7)
Hysterectomy
Oral contraceptive pills
Estrogen replacement therapy
MRI Scans + Obesity (8)
Obesity
Abnormal brain MRI
Brain MRI
Cervical spine MRI
Thoracic spine MRI
Blood Tests (9)
Erythrocyte sedimintation rate
Lyme
B12
ANA panel
Anti-cardiolipin antibody
Zinc
Cerebrospinal fluid exam
genetic risk score (wGRS) based on genetic susceptibility loci in the context of environmental risk factors. However, prior
research relies on specialized measurements that are performed to confirm a MS diagnosis. The approaches suggested do not
generalize to all patients and fail to allow for early diagnosis and intervention of high-risk MS patients.
III. MATERIALS AND METHODS
A. Data
Our retrospective study used de-identified patient data from the NorthShore Enterprise Data Warehouse (EDW). The data
was collected from January 2006 to July 2012 and contained information pertaining to demographics, medications, medical
encounters and procedures.
The study examined adults (≥ 18 years of age) with complete demographic data (age, gender, ethnicity, and race). Any
individual diagnosed with an MS ICD-9 code (“340”) during a Neurology office visit was selected as a case patient. 1,456 case
patients were identified in the NorthShore EDW. However, only 737 of the patients had recorded electronic medical encounters
prior to the initial diagnosis date. For each of the 737 case patients, four control subjects with matching age and gender were
selected from the general population for a total of 3,685 patients.
B. Predictor Variables
A comprehensive list of potential features was curated from prior MS research, detailed in section II. The list was also
expanded to include common vaccinations, cancers, mental illnesses, and autoimmune diseases. Unfortunately some of the
variables, such as lifestyle factors (smoking and alcohol use) and diet were unrecorded in the EMR. In addition, some diseases
were also excluded because none of the patients received the particular medical diagnosis during the study period. Table I
enumerates the features used in our retrospective study.
The initial MS diagnosis date is used to define t0 for case patients. Since control patients did not have a MS diagnosis, t0
is a randomly selected from the patient’s encounter date. Figure 1 shows the frequency of the number of encounters with the
same date and location prior to t0. Case patients generally have a low number of previous encounters while there is a more
even distribution amongst the control patients. An alternative option was to use the same t0 for matching control patients.
However, this exacerbated the discrepancy in the number of encounters prior to t0 between case and control. Thus, a random
encounter date was used to define t0 for control patients.
All data, except those related to family history, obtained after t0 were discarded to limit the potential effects of confounding
factors. Family medical history spanned the entire study period because collection time is unimportant. A patient may fail to
disclose all the family history in the first few medical encounters but reveals the information in later encounters after being
diagnosed with a certain disease.
4Fig. 1: Histogram of the number of encounters before t0
Binary values were used to indicate the presence of a particular medical diagnosis (ICD-9 code) found in a patient’s encounter
data prior to t0. The vaccination, reproductive, and family medical history was extracted in a similar fashion, denoting the
existing of specific supplemental classification codes (ICD-9 V codes). MRI scan features, except for an abnormal MRI result
which was extracted via an ICD-9 code, signified the presence of specific medical procedure requests. Given the sparsity of
numeric blood tests results, the feature was converted to three levels: (1) Unobserved, (2) Observed-Normal, and (3) Observed-
Abnormal based on the ranges provided by the EDW. The entire feature set was represented using a binary matrix, where
categorical variables were converted to dummy variables.
C. Model Development
Multivariate logistic regression models were used to predict a MS diagnosis at the next encounter. The selection of logistic
regression model was motivated by the popularity of the model in the medical community, the simplicity of the model, and the
interpretability of the results. To evaluate the effect on accuracy of specific predictor categories, new features were introduced
in the order defined by Table I. The first feature set contained only demographic and family history data, and was designed to
mimic the information available at the first office visit. The last feature set contains all the predictor variables listed in Table
I. For each feature set, two sets of logistic regression models were trained: (1) forward stepwise model selection by Akaike
information criterion (AIC) and (2) backward stepwise model selection by AIC. Stepwise model selection by AIC is used
to minimize the model complexity, or encourage a sparser feature representation, without sacrificing predictive performance.
10-fold cross validation was used to estimate the accuracy of each model.
IV. RESULTS
A. Feature Set Comparisons
Figure 2 shows the area under the receiver operating characteristic curve (AUC) for each feature set and model selection.
Both feature selection methods result in similar predictive performance. Given only data that is available at the first office
visit (demographic and family history), the forward selection model with an AUC of 0.538 ± 0.016 marginally outperforms
random guess. Feature set 2, an expansion of the features to include autoimmune disorder diagnoses, increases the AUC by
0.072. The performance then remains stagnant with the addition of the microbial, mental illness, and cancer feature categories.
However, vaccinations, MRI scans, and blood test results boosted the predictive performance. Using all the available features
(feature set 9), the forward and backward feature selection models predict an MS diagnosis at the next visit with an AUC of
0.724± 0.033 and 0.718± 0.030 respectively.
Stepwise feature selection using AIC produces a model using a sparse set of features. Figure 3 displays the comparison for
the number of selected variables per feature set. The number of features selected with backward stepwise regression remains
fairly constant for each feature set. This suggests the later categories (blood test results and MRI scans) are more informative.
In addition, for feature sets 7-9, the backward selection method results in a sparse set of features. Both selection models on
feature set 9 select less than 15% of the potential features.
Figure 4 compares the joint predicted probabilities of consecutive feature sets for case patients and illustrates the effects
of adding specific feature categories. Some of the transitions have been omitted since they are similar to the first feature set
transition (1→2). The addition of autoimmune disease diagnoses (1→2) generally increases the predicted risk. The trend is
most noticeable in the transition plot from feature 7 to 8, where the points lie predominately above the dotted line. Inclusion
of blood test results (8→9) marginally improves the predicted risk but it also decreases a substantial portion of patients with
high risk in the previous model.
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Fig. 2: A comparison of the AUC as categories of variables are added to the feature set.
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Fig. 3: A box plot of the number of variables selected per feature set and selection method.
A joint density estimate of two consecutive feature sets for the control patients is demonstrated in Figure 5. For the first
transition (1→2), the improvement to predictive performance can also be traced to the decrease in the predicted risk of low
risk MS patients. In addition, the figure illustrates that as the feature is expanded, the density slowly shifts away from the top
right corner to the bottom half of the plot. The transition from feature set 8 to 9 shows that the predicted risk is distributed
more evenly for the control patients compared to the first feature set, where the probabilities are lie around 0.21.
Figures 4 and 5 show the dispersion of risk probabilities as more features are introduced. The addition of features related
to MRI scans, or feature set 8, improves the separation between case and control through higher predicted probabilities for
high-risk patients. The AUC improvement obtained from the inclusion of blood test results, feature set 9, can be primarily
attributed to the decrease in predicted risk of control patients. These figures provide a graphical analysis of the benefits of
specific feature categories.
B. Feature Set 9 Results
We further focus on the model with the best predictive performance, the forward selection model trained on all the features
(feature set 9). Table II summarizes the variables for which the magnitude of the coefficient is larger than 1 in the majority of
the folds. The table also displays the number of case and control patients with the feature, the odds ratio, and the p-value from
a chi-square test to determine the significance of the variable. If we use p-value as an initial filter with α=0.05, the following
features would be eliminated: EBV; Bell’s Palsy; colon cancer; family history of mental illness, MS, and inflammatory bowel
disease; varicella vaccine, schizophrenia, and the Haemophilus influenzae type b vaccine. However, the selection of some of
these variables, such as history of mental illness and varicella vaccine, is surprising given the lack of sufficient evidence in
prior work to support their effect on the development of MS.
Figure 6 shows the distribution of predicted risk values. The figure shows that even with all the features listed in Table
I, there is still a considerable overlap of predicted probabilities between case and control patients. Better separation between
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Fig. 4: A scatterplot comparison of the predicted probabilities between consecutive feature sets for 737 case patients. The
dotted line signifies no change in predicted risk.
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Fig. 5: A 2D kernel density estimate of the previous feature set and next feature set predicted probabilities for 2,948 control
patients.
these two classes can improve the risk prediction accuracy. The plot suggests incorporation of additional diagnoses or temporal
aspects of existing diagnoses may be necessary to improve model performance.
Figure 7 contains the performance plots for the forward selection models trained on feature set 1 and feature set 9. Figure
7(a) demonstrates the noticeable improvement using all the available features. Additionally, the model trained on feature set
1, demographics and family history features, barely outperforms random chance. The tradeoff between sensitivity, specificity,
and positive predictive value can be seen in Figure 7(b). Feature set 9 has a higher intersection between the sensitivity and
specificity curves, which is summarized in Table III. In addition, the full-featured model generally achieves a better positive
predictive value for all threshold values. However, the positive predictive value and sensitivity curves cross at the value ∼ 0.40.
At this point, we can accurately diagnose 40% of the case patients, but only 2 out of every 5 patients predicted to have a high
risk of MS will be diagnosed with MS at the next office visit, a high number of false positives.
C. Discussion
The results demonstrate reasonable predictive accuracy using all the available features. One potential hindrance lies in the
current feature construction. As Figure 1 shows, there are a limited number of encounters prior to t0 for case patients. Thus, it
is difficult to determine whether an unobserved diagnosis may be due to the lack of longitudinal data (the patient was diagnosed
prior to the study period). Additionally, certain diagnoses, such as EBV, can only be verified through culture samples which
are not performed for every patient.
Another limitation of our study is the reliance on ICD-9 and procedure codes. A patient may exhibit all the clinical symptoms
for a specific disease but it is not present in the encounter data because the disorder has not been diagnosed. The ambiguity
of ICD9-codes and diagnostic discrepancies between medical doctors can also impact our feature construction. Moreover, the
blood test results’ conversion to a categorical feature may be inaccurate as the testing protocol may have changed during the
study window. Therefore, a patient’s feature vector may not accurately reflect their medical history.
7Feature Beta Case Control Odds ratio p-value
Presence CSF oligoclonal bands 16.255±0.545 27 0 ∞ 0.000
Mental Illness (FH) 6.298±3.101 3 1 3 0.033
EBV 3.974±3.924 3 2 1.5 0.093
Abnormal brain MRI 2.877±0.313 10 4 2.5 0.000
Unobserved B12 2.527±0.149 674 2619 0.257 0.047
Obs-Normal B12 2.375±0.175 54 162 0.333 0.071
Obs-Normal ANA SSB 1.141±0.269 57 95 0.6 0.000
Bell’s Palsy 1.889±0.295 2 3 0.667 0.576
Diabetes -1.036±0.078 19 224 0.085 0.000
Obs-Normal ANA DS -1.066±0.122 44 78 0.564 0.000
Oral contraceptive -1.244±0.205 2 35 0.057 0.043
DTP vaccine -1.829±0.126 12 327 0.037 0.000
Unobserved Lyme Test -1.980±0.099 692 2924 0.237 0.000
Colon cancer -2.927±4.072 2 15 0.133 0.584
Asian race -2.925±0.234 2 93 0.022 0.000
MS (FH) -3.356±4.307 2 19 0.105 0.023
Unobserved CSF IGG synthesis -4.841±0.296 700 2946 0.238 0.000
Varicella vaccine -15.161±0.087 0 13 0 0.145
HPV vaccine -15.728±2.188 0 82 0 0.000
Schizophrenia -15.763±0.369 0 10 0 0.235
Estrogen replacement -15.823±0.209 0 22 0 0.037
IBD (FH) -17.236±0.420 0 3 0 0.885
HIB vaccine -18.156±0.521 0 2 0 1.000
TABLE II: Mean coefficient values, odds ratio, and p-value for variables picked in at least 5 of the 10 folds with |β| > 1
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Fig. 6: Box plot of the predicted probabilities using a forward selection model on all the features.
Our study also suggests incorporating additional features. Given that some of the variables were unrecorded in the structured
portion of the EMR, parsing through the clinical notes could result in information regarding lifestyle factors, diet, detailed
family and medical history. In addition, temporal aspects of the medical diagnoses were not included in our feature set since
the data was confined to medical encounters over a 6-year period.
Feature Set Cutoff Sensitivity Sensitivity PPV
1 0.212 0.528 0.528 0.218
9 0.241 0.647 0.647 0.314
TABLE III: The intersection of the sensitivity and specificity curve from Figure 7(b).
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(a) ROC curves compared to random assignment
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Fig. 7: Model performance plots for feature sets 1 and 9.
V. CONCLUSION
This paper presented a risk prediction model from EMRs to help address the difficulty of early diagnosis in MS patients. A
sparse set of features were selected to minimize model complexity while maintaining reasonable predictive performance. Our
results show we are able to help identify patients at high-risk of developing MS, in spite of a limited sample of patient data.
In addition, our models have the ability to generalize to other healthcare systems as we rely only on components commonly
found in electronic patient data.
The work demonstrates the potential of leveraging EMRs to aid medical professionals with difficult tasks, especially with
early disease diagnosis. Future work will focus on incorporating temporal components, such as time of diagnosis, into the
model, decreasing the false positive rate, and integrating a larger control population.
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